Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab (AK104) in Advanced Solid Tumors and Gastric/GEJ Cancer
NCT03852251Phase 2Completed
- Sponsor
- Akeso, Inc.
- Start
- Jan 2019
- Primary completion
- Mar 2024
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of cadonilimab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and solid tumor (advanced stage) (2 arms), sponsored by Akeso, Inc. Primary endpoints: Adverse Events, Dose-Limiting Toxicities at 4 weeks and 1 more. Started Jan 2019; status: completed.
02
Drugs
cadonilimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomasolid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03852251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03852251.